Quantum Surgical is a Montpellier-based medical robotics company developing the Epione system — a robotic platform for minimally invasive thermal ablation of liver tumors. Founded in 2017 by Pierre Morel and a team combining interventional radiology expertise with robotics engineering, the company has built one of the most clinically significant medical robotics platforms to emerge from the French health innovation ecosystem. With approximately €60 million raised across multiple funding rounds, CE marking received in 2020, and FDA 510(k) clearance obtained in 2022, Quantum Surgical has achieved the dual-market regulatory approvals required to compete in both European and US interventional oncology markets.
Quantum Surgical’s clinical proposition addresses a significant unmet need in liver cancer treatment. Liver tumors — both primary hepatocellular carcinoma and metastatic disease (most commonly from colorectal cancer) — are frequently treated through percutaneous thermal ablation, where a needle-like probe is inserted through the skin into the tumor and heat (microwave or radiofrequency energy) is applied to destroy the cancer cells. The challenge is targeting precision: the probe must be placed with millimeter accuracy within a moving, breathing organ, while the physician simultaneously manages anesthesia, imaging interpretation, probe positioning, and energy delivery. Errors in probe placement lead to incomplete ablation and disease recurrence.
France 2030 Funding & Projects
Quantum Surgical is a recipient of France 2030 health innovation funding through Bpifrance’s health technology programs, which have prioritized medical robotics as a strategic domain where France has both academic expertise (multiple world-class interventional radiology centers including CHU Montpellier, CHU Lyon, and Institut Gustave Roussy) and commercial opportunity. The company’s Montpellier base connects it to the BioValley Languedoc-Roussillon health technology cluster, which France 2030 supports as part of its regional innovation strategy.
The clinical trial work underpinning Epione’s regulatory approvals was conducted at French university hospitals under programs co-funded by the French Ministry of Health and France’s cancer research organization (INCa — Institut National du Cancer). This institutional support reflects a distinctive feature of France’s health innovation ecosystem: close integration between academic medical centers, clinical researchers, and startups at the early development stages that the US FDA pre-submission pathway makes more distant.
France’s health innovation programs also supported the development of Quantum Surgical’s proprietary real-time imaging algorithms — the software that integrates live ultrasound imaging with pre-procedural CT scan data to provide the physician with a continuously updated 3D map of the tumor and probe position during the ablation procedure. This image fusion capability is the technical core of Epione’s clinical differentiation.
Technology & Innovation
The Epione system’s technical architecture combines four integrated capabilities: a robotic arm that positions and stabilizes the ablation probe with sub-millimeter precision; a real-time ultrasound imaging module that tracks the probe’s position relative to the tumor and surrounding structures; a proprietary image fusion algorithm that overlays pre-procedural CT or MRI data onto the live ultrasound image; and an energy delivery system that controls the ablation treatment parameters based on real-time feedback.
The critical innovation is the real-time image fusion software. Liver tumors are frequently poorly visible on ultrasound alone — the organ’s parenchyma (tissue) appears relatively homogeneous, making tumors that are clearly visible on CT or MRI difficult to distinguish in real-time ultrasound. By registering the pre-procedural 3D anatomy (from CT or MRI, which shows the tumor clearly) with the real-time ultrasound image (which shows the current anatomy including breathing motion), Epione can continuously display where the tumor is relative to the probe, compensating for respiratory movement that can shift the liver by several centimeters during normal breathing.
This image fusion capability directly addresses the primary technical challenge of liver ablation — maintaining targeting accuracy throughout the procedure despite organ motion — and is the reason Quantum Surgical’s clinical trial data showed significantly improved complete ablation rates compared to conventional ultrasound-guided procedures.
The robotic arm provides two additional advantages beyond the imaging contribution: first, it stabilizes the probe position during the critical ablation phase, preventing unintended probe displacement from patient movement or operator hand tremor; second, it records the exact probe trajectory and position, creating an auditable procedure record that supports reimbursement documentation and quality improvement.
Competitive Landscape
Medical robotics for interventional oncology is a growing but still nascent market. Quantum Surgical’s primary competition comes from:
Stereotaxis (US): Robotic magnetic navigation for cardiac and interventional procedures, with a different technology base.
Accuray (US): Robotic radiation delivery (CyberKnife, Radixact) for stereotactic radiosurgery — a different treatment modality (external beam radiation rather than percutaneous ablation) but targeting overlapping patient populations.
Intuitive Surgical (US, Da Vinci): The dominant surgical robot company, focused on laparoscopic and minimally invasive surgery. Da Vinci is used for some liver resection procedures but not for percutaneous ablation — Quantum Surgical’s specific indication.
iQUR / Medtronic / Boston Scientific: Traditional ablation catheter and probe manufacturers who are potential competitors if they develop robotic guidance add-ons for their existing platforms.
The absence of a dominant robotic ablation competitor in Quantum Surgical’s specific indication creates a greenfield opportunity for first-mover establishment. The company’s CE mark and FDA clearance provide regulatory moats that take 3-5 years for competitors to replicate.
Investor Perspective
Quantum Surgical’s investment profile is representative of France’s health robotics sector: strong clinical evidence, credible regulatory clearances, and a commercially significant indication with a clear reimbursement pathway, balanced against the long sales cycles of capital medical equipment sales to hospital systems.
The primary growth challenge is hospital adoption. Hospitals are conservative buyers of capital equipment — they require clinical evidence, peer-reviewed publications, physician champion relationships, and reimbursement clarity before committing to a new robotic system. Quantum Surgical’s commercial strategy focuses on establishing Epione at leading French and European academic medical centers first (CHU Montpellier, Institut Gustave Roussy), using those reference sites to build the evidence base and physician champion network required for broader hospital rollout.
The US market represents the largest commercial opportunity and the most competitive selling environment. FDA clearance is a prerequisite achieved; commercial success depends on building a US sales organization or partnership with a US-based medical device distributor.
Related Companies
- Sanofi — French health innovation ecosystem, pharmaceutical development context
- bioMérieux — French health technology anchor
- DNA Script — French frontier health biotech peer
- Ipsen — Oncology therapeutic context (Cabometyx for HCC)
- Health Data Hub — French health data infrastructure for clinical trial support